Date: 2013-04-16
Type of information: R&D agreement
Compound: RNA-targeted medicines using Santaris Pharma A/S Locked Nucleic Acid (LNA) Drug Platform
Company: Santaris Pharma (Denmark) BMS (USA - NY)
Therapeutic area: undisclosed
Type agreement: R&D
Action mechanism:
Disease: undisclosed
Details: * On April 16, 2013, Santaris Pharma, a privately held biopharmaceutical company focused on developing medicines targeted to disease-related mRNAs and microRNAs, has announced a worldwide strategic alliance with BMS to discover and develop novel medicines using Santaris Pharma's proprietary Locked Nucleic Acid (LNA) Drug Platform. This platform is used to deliver LNA-based drug candidates against RNA targets, both mRNA and microRNA, for a range of diseases including infectious and inflammatory diseases, cardiometabolic disorders, cancer and rare genetic disorders.
Financial terms: Under the terms of the agreement, Santaris Pharma will receive an upfront payment of $10 million, up to $90 million in potential milestone payments per product and funding of ongoing discovery and research activities. In addition, Santaris Pharma will be eligible to receive royalties on the worldwide sales of all medicines arising from the alliance.
Latest news:
